MicroPort® MedBot™’s Toumai® Robot Marks a Significant Milestone by Conducting Its First Surgery in an International Setting

Shanghai, China, 17 April, 2024 – Recently, the Toumai® Laparoscopic Surgical Robot successfully performed its first clinical operation outside of China, conducting a radical prostatectomy to treat prostate cancer. It also marked the introduction of the first surgical robot in the country, heralding a new era of robot-assisted minimally invasive surgery. Following the integration of the Toumai® robot, the hospital has offered more efficient and intuitive surgical solutions. This advancement has led to more precise and safer surgical treatments, significantly improving patient satisfaction.

Prostatectomy is known for its complexity due to the deep pelvic location of the prostate and its rich surrounding vasculature. 1 The Toumai® robot addresses this complexity through its 3D high-definition stereo vision and highly flexible wrist-moved surgical instruments, which allowed hospital staff to perform this procedure deftly. Key operational steps included dissecting and freeing the prostate, preserving the neurovascular bundle (NVB), detaching the bladder neck, and reconstructing the urethra. 2 This procedure was executed smoothly, with the patient maintaining stable vital signs and minimal blood loss.

"The robot-assisted laparoscopic radical prostatectomy is indeed the 'gold standard' for prostate cancer surgery, offering greater precision than traditional methods," stated the lead surgeon after the operation. "During this procedure, we were able to accurately identify nerves, blood vessels, and tissue layers, enabling precise excision while effectively isolating the urethra. This led to quicker patient recovery and fewer complications. Introducing the Toumai® robot has proven to be a correct decision, and we are optimistic about its future impact on advancing minimally invasive treatments."

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort® MedBot™, remarked, “The successful international debut of our Toumai® robot, highly praised by leading surgeons, represents a significant milestone in its global commercialization. This success stems from our relentless dedication to innovation, quality, service excellence, and overall value. Looking ahead, we aim to expand our global presence by leveraging cutting-edge medical manufacturing technologies. Our goal is clear: to meet surgical needs worldwide and enhance the reach of our medical technologies, ultimately benefiting patients globally.”

About MicroPort® MedBot

Founded in 2015, MicroPort® MedBot™ (Shanghai MicroPort MedBot Group Co., Ltd.; HKEX: 02252), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is currently the only surgical robot company in the world with businesses covering six promising subsectors of surgical robots including endoscopy, orthopedics, vascular intervention, natural orifice surgery, percutaneous puncture and medical aesthetics. MicroPort® MedBot™ is committed to meeting the growing demand for cutting-edge robotic surgery by integrating advanced research on robotics, control algorithms, electrical engineering, image-based navigation and precision imaging. MicroPort® MedBot™ provides comprehensive intelligent surgical solutions to lead the advancement of robotic surgery and shape the era of super intelligent surgery so patients everywhere can continue living better and longer lives.

More information is available at www.medbotsurgical.com/en


  1. Worthington JF. Treatment for Prostate Cancer: Surgery [online]. [cited 2024, Apr 29]. Retrieved from: URL: https://www.pcf.org/c/treatmen....
  2. Huynh LM, Ahlering TE. Robot-assisted radical prostatectomy: a step-by-step guide. J Endourol 2018;32(S1):S-28.